CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months.

Trial Profile

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Exenatide (Primary) ; Insulins
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CHOICE
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 14 Apr 2010 Additional trial location (Greece) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top